ProfileGDS5678 / 1416547_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 96% 96% 96% 96% 95% 96% 97% 96% 96% 96% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.8391996
GSM967853U87-EV human glioblastoma xenograft - Control 29.0216696
GSM967854U87-EV human glioblastoma xenograft - Control 39.1123396
GSM967855U87-EV human glioblastoma xenograft - Control 49.2376796
GSM967856U87-EV human glioblastoma xenograft - Control 59.099496
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.429196
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.3587695
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.9726196
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.320197
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.0472596
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.6191696
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.9296196
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.9159296
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.0332596